2nd Quarter - Report
INTERNATIONAL MYELOMA FOUNDATION for INTERNATIONAL MYELOMA FOUNDATION
Income
—
Expenses
$36,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 2746 Cancer Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARIN ASSERO | — |
Medical/Disease Research/Clinical Labs MED
HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARIN ASSERO | — |
Budget/Appropriations BUD
S.3295/ (no House number posted yet), Labor HHS & Education, FY 2013 H.R. 5973/S. 2375, Agriculture, FY 2013
| Lobbyist | Covered position, as disclosed |
|---|---|
| ARIN ASSERO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.